Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients.

Details

Ressource 1Download: serval:BIB_67277776B4D5.P001 (97.93 [Ko])
State: Public
Version: author
License: Not specified
It was possible to publish this article open access thanks to a Swiss National Licence with the publisher.
Serval ID
serval:BIB_67277776B4D5
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients.
Journal
Annals of Oncology
Author(s)
Peters S., Voelter V., Zografos L., Pampallona S., Popescu R., Gillet M., Bosshard W., Fiorentini G., Lotem M., Weitzen R., Keilholz U., Humblet Y., Piperno-Neumann S., Stupp R., Leyvraz S.
ISSN
0923-7534
Publication state
Published
Issued date
2006
Peer-reviewed
Oui
Volume
17
Number
4
Pages
578-583
Language
english
Abstract
BACKGROUND: Exclusive liver metastases occur in up to 40% of patients with uveal melanoma associated with a median survival of 2-7 months. Single agent response rates with commonly available chemotherapy are below 10%. We have investigated the use of fotemustine via direct intra-arterial hepatic (i.a.h.) administration in patients with uveal melanoma metastases. PATIENTS AND METHODS: A total of 101 patients from seven centers were treated with i.a.h. fotemustine, administered intra-arterially weekly for a 4-week induction period, and then as a maintenance treatment every 3 weeks until disease progression, unacceptable toxicity or patient refusal. RESULTS: A median of eight fotemustine infusions per patient were delivered (range 1-26). Catheter related complications occurred in 23% of patients; however, this required treatment discontinuation in only 10% of the patients. The overall response rate was 36% with a median overall survival of 15 months and a 2-year survival rate of 29%. LDH, time between diagnosis and treatment start and gender were significant predictors of survival. CONCLUSIONS: Locoregional treatment with fotemustine is well tolerated and seems to improve outcome of this poor prognosis patient population. Median survival rates are among the longest reported and one-third of the patients are still alive at 2 years.
Keywords
Adult, Aged, Antineoplastic Agents, Female, Humans, Injections, Intra-Arterial, Liver Neoplasms, Male, Melanoma, Middle Aged, Nitrosourea Compounds, Organophosphorus Compounds, Uveal Neoplasms
Pubmed
Web of science
Open Access
Yes
Create date
28/01/2008 14:10
Last modification date
25/09/2019 7:09
Usage data